These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
N/A | ||||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| ☒ | Smaller reporting company | |||||
| Emerging growth company | ||||||
1 |
||||
1 |
||||
1 |
||||
2 |
||||
3 |
||||
4 |
||||
5 |
||||
14 |
||||
16 |
||||
16 |
||||
17 |
||||
17 |
||||
17 |
||||
17 |
||||
17 |
||||
17 |
||||
17 |
||||
18 |
||||
19 |
||||
June 30, 2022 |
December 31, 2021 |
|||||||
(Unaudited) |
(Audited) |
|||||||
| ASSETS |
||||||||
| Current asset – cash |
$ | $ | ||||||
| Deferred offering costs |
||||||||
| |
|
|
|
|||||
| Total Assets |
$ | $ | ||||||
| |
|
|
|
|||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
| Current Liabilities |
||||||||
| Promissory note – related party |
$ | $ | ||||||
| Total Current Liabilities |
||||||||
| |
|
|
|
|||||
| Commitments and Contingencies |
||||||||
| Stockholders’ Equity |
||||||||
| Ordinary Shares, par value $ (1) |
||||||||
| Additional paid-in capital |
||||||||
| Accumulated deficit |
( |
) | ( |
) | ||||
| |
|
|
|
|||||
| Total Stockholders’ Equity |
||||||||
| |
|
|
|
|||||
| Total Liabilities and Stockholders’ Equity |
$ | $ | ||||||
| |
|
|
|
|||||
| (1) | Includes an aggregate of over-allotment is not exercised in full or in part. |
Three months ended June 30, 2022 |
Six months ended June 30, 2022 |
For the Period from March 3, 2021 (inception) through June 30, 2021 |
Three months ended June 30, 2021 |
|||||||||||||
(Unaudited) |
(Unaudited) |
(Unaudited) |
(Unaudited) |
|||||||||||||
Operating costs |
$ | — | $ | — | $ | ( |
) | $ |
— |
|||||||
Net Loss |
— | — | $ | ( |
) | — |
||||||||||
Weighted average shares outstanding, basic and diluted (1) |
||||||||||||||||
Basic and diluted net loss per ordinary share |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
| (1) | Excludes an aggregate of |
Ordinary Shares |
Additional Paid-in Capital |
Accumulated Deficit |
Total Stockholders’ Equity |
|||||||||||||||||
Shares (1) |
Amount |
|||||||||||||||||||
Balance – December 31, 2021 (Audited) |
$ |
$ | $ |
( |
) |
$ |
||||||||||||||
Net loss |
— | — | — | — | ||||||||||||||||
Balance – March 31, 2022 (Unaudited) |
$ |
$ | $ |
( |
) |
$ |
||||||||||||||
Net loss |
— | — | — | — | ||||||||||||||||
Balance – June 30, 2022 (Unaudited) |
$ |
$ | $ |
( |
) |
$ |
||||||||||||||
| (1) | Includes an aggregate of over-allotment is not exercised in full or in part. |
Ordinary Shares |
Additional Paid-In Capital |
Accumulated Deficit |
Total Stockholders’ Equity |
|||||||||||||||||
Shares |
Amount |
|||||||||||||||||||
Balance – March 3, 2021 (inception) |
$ | $ | $ | $ | ||||||||||||||||
Net loss |
— |
— |
— |
( |
) |
( |
) | |||||||||||||
Balance – March 31, 2021 (Unaudited) |
( |
) |
( |
) | ||||||||||||||||
Issuance of Ordinary shares to Sponsor (1) |
— | |||||||||||||||||||
Balance – June 30, 2021 (Unaudited) |
$ |
$ |
$ |
( |
) |
$ |
||||||||||||||
| (1) | Includes an aggregate of |
Six months ended June 30, 2022 |
For the Period from March 3, 2021 (inception) through June 30, 2021 |
|||||||
(Unaudited) |
(Unaudited) |
|||||||
| Cash flows from Operating Activities: |
||||||||
| Net Loss |
$ | — | $ | ( |
) | |||
| Changes in operating assets and liabilities: |
||||||||
| Operating costs |
— |
|||||||
| |
|
|
|
|||||
| Net cash used in operating activities |
||||||||
| Cash Flows from Financing Activities: |
||||||||
| Proceeds from issuance of Ordinary shares to Sponsor |
— | |||||||
| Proceeds from Promissory note |
— | |||||||
| Payment of offering costs |
( |
) | ( |
) | ||||
| |
|
|
|
|||||
| Net cash provided by (used in) financing activities |
( |
) | ||||||
| |
|
|
|
|||||
| Net Change in Cash |
( |
) | ||||||
| Cash – Beginning of period |
||||||||
| |
|
|
|
|||||
| Cash – Ending of period |
$ | $ | ||||||
| |
|
|
|
|||||
| Supplemental Disclosures of Noncash Financing Activities |
||||||||
| Deferred offering costs included in promissory note |
||||||||
| • | at any time while the Warrants are exercisable, |
| • | upon not less than |
| • | if, and only if, the reported last sale price of the ordinary share equals or exceeds $ |
| • | if, and only if, there is a current registration statement in effect with respect to the ordinary share underlying such warrants at the time of redemption and for the entire |
| • | $70,000 of expenses for the legal, accounting and other third-party expenses in connection with initial business combination; |
| • | $100,000 of expenses for the search for target businesses, due diligence investigations, structuring and negotiating of our initial business combination; |
| • | $50,000 of expenses relating to our SEC filing obligations and other legal and accounting fees related to regulatory reporting obligations; |
| • | $180,000 of expenses for the payment for utilities and secretarial and administrative support; and |
| • | $100,000 for general working capital that will be used for miscellaneous expenses. |
| * | These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing. |
| Dated: August 12, 2022 | EMBRACE CHANGE ACQUISITION CORP. | |||||
| By: | /s/ Zheng Yuan | |||||
| Name: | Zheng Yuan | |||||
| Title: | Chief Financial Officer (Principal Financial and Accounting Officer) | |||||
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|